190 related articles for article (PubMed ID: 30956763)
1. Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced
van Herpen CML; Agarwala SS; Hauschild A; Berking C; Beck JT; Schadendorf D; Jansen R; Queirolo P; Ascierto PA; Blank CU; Heinrich MC; Pal RR; Derti A; Antona V; Nauwelaerts H; Zubel A; Dummer R
Oncotarget; 2019 Mar; 10(19):1850-1859. PubMed ID: 30956763
[No Abstract] [Full Text] [Related]
2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
3. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
6. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.
Niessner H; Hüsch A; Kosnopfel C; Meinhardt M; Westphal D; Meier F; Schilling B; Sinnberg T
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067230
[TBL] [Abstract][Full Text] [Related]
7. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
8. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
Finn RS; Ahn DH; Javle MM; Tan BR; Weekes CD; Bendell JC; Patnaik A; Khan GN; Laheru D; Chavira R; Christy-Bittel J; Barrett E; Sawyer MB; Bekaii-Saab TS
Invest New Drugs; 2018 Dec; 36(6):1037-1043. PubMed ID: 29785570
[TBL] [Abstract][Full Text] [Related]
10. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Schadendorf D; Ascierto PA; Arance A; Dutriaux C; Di Giacomo AM; Rutkowski P; Del Vecchio M; Gutzmer R; Mandala M; Thomas L; Demidov L; Garbe C; Hogg D; Liszkay G; Queirolo P; Wasserman E; Ford J; Weill M; Sirulnik LA; Jehl V; Bozón V; Long GV; Flaherty K
Lancet Oncol; 2017 Apr; 18(4):435-445. PubMed ID: 28284557
[TBL] [Abstract][Full Text] [Related]
11. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
12. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition and immune responses in advanced melanoma.
Dummer R; Ramelyte E; Schindler S; Thürigen O; Levesque MP; Koelblinger P
Oncoimmunology; 2017; 6(8):e1335843. PubMed ID: 28919996
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
[TBL] [Abstract][Full Text] [Related]
15. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
16. Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
Urner-Bloch U; Urner M; Stieger P; Galliker N; Winterton N; Zubel A; Moutouh-de Parseval L; Dummer R; Goldinger SM
Ann Oncol; 2014 Jul; 25(7):1437-1441. PubMed ID: 24864047
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
Schuler M; Zimmer L; Kim KB; Sosman JA; Ascierto PA; Postow MA; De Vos FYFL; van Herpen CML; Carlino MS; Johnson DB; Berking C; Reddy MB; Harney AS; Berlin JD; Amaria RN
Clin Cancer Res; 2022 Jul; 28(14):3002-3010. PubMed ID: 35294522
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
20. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
Richman J; Martin-Liberal J; Diem S; Larkin J
Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
